Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (181-190 of 238) with videos related to

Pageof 24
Sort By:
Scientific Reports|November 9, 2022
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairmentMagda S C Fontes, Jasper Dingemanse, Atef Halabi, et al.
Journal of Psychopharmacology (Oxford, England)|December 6, 2024
Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive functionMassimo Magliocca, Ingrid Koopmans, Cedric Vaillant, et al.
Clinical Drug Investigation|October 22, 2014
A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trialDaniela Baldoni, Shirin Bruderer, Andreas Krause, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 20, 2019
Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjectsMike Ufer, Christine Huynh, Jan Jaap van Lier, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 9, 2015
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist SelexipagPriska Kaufmann, Kaori Okubo, Shirin Bruderer, et al.
Orphanet Journal of Rare Diseases|October 28, 2020
The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjectsMarkus S Mueller, Patricia N Sidharta, Christine Voors-Pette, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 31, 2012
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humansShirin Bruderer, Gérard Hopfgartner, Michael Seiberling, et al.
Clinical and Translational Science|May 18, 2022
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrelUta Schilling, Chih-Hsuan Hsin, Stephane Delahaye, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 28, 2020
Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P<sub>1</sub> receptor modulator in healthy subjectsMarie-Laure Boof, Jan Jaap van Lier, Stephen English, et al.
Clinical Pharmacokinetics|December 28, 2021
Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y<sub>12</sub> Receptor Antagonist Selatogrel in Healthy SubjectsIsabelle Zenklusen, Chih-Hsuan Hsin, Uta Schilling, et al.
Pageof 24

Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
Scientific Reports|November 9, 2022
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairmentMagda S C Fontes, Jasper Dingemanse, Atef Halabi, et al.
Journal of Psychopharmacology (Oxford, England)|December 6, 2024
Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive functionMassimo Magliocca, Ingrid Koopmans, Cedric Vaillant, et al.
Clinical Drug Investigation|October 22, 2014
A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trialDaniela Baldoni, Shirin Bruderer, Andreas Krause, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 20, 2019
Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjectsMike Ufer, Christine Huynh, Jan Jaap van Lier, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 9, 2015
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist SelexipagPriska Kaufmann, Kaori Okubo, Shirin Bruderer, et al.
Orphanet Journal of Rare Diseases|October 28, 2020
The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjectsMarkus S Mueller, Patricia N Sidharta, Christine Voors-Pette, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 31, 2012
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humansShirin Bruderer, Gérard Hopfgartner, Michael Seiberling, et al.
Clinical and Translational Science|May 18, 2022
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrelUta Schilling, Chih-Hsuan Hsin, Stephane Delahaye, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 28, 2020
Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P<sub>1</sub> receptor modulator in healthy subjectsMarie-Laure Boof, Jan Jaap van Lier, Stephen English, et al.
Clinical Pharmacokinetics|December 28, 2021
Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y<sub>12</sub> Receptor Antagonist Selatogrel in Healthy SubjectsIsabelle Zenklusen, Chih-Hsuan Hsin, Uta Schilling, et al.
Pageof 24